

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

This notice is to inform you of a product recall involving **Diltiazem Hydrochloride Extended Release Capsules, 360 mg**

| Product Name | Package Description | Lot Number | NDCNumber | Expiration Date |
|--|----------------------------|-------------------|------------------|------------------------|
| Diltiazem Hydrochloride Extended Release Capsules, 360mg | 90 Count | HAC3120A | 47335-679-8 1 | 04/2023 |
| | 90 Count | HAC3121A | 47335-679-8 1 | 04/2023 |
| | 90 Count | HAC4460A | 47335-679-8 1 | 10/2023 |
| | 90 Count | HAD0365A | 47335-679-8 1 | 12/2023 |
| | 90 Count | HAD1452A | 47335-679-8 1 | 02/2024 |

Sun Pharmaceuticals Inc. has initiated this recall due to related substance results (Deacetyl Diltiazem Hydrochloride Impurity) that were reported above the specification limit during stability testing; and not meeting to USP requirement for dissolution testing in FDA Laboratory. This recall should be carried out to the **retail** level.

Sun Pharmaceutical Industries Inc. initiated shipment of this product in November 2, 2021.